{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T05:48:04Z","timestamp":1792388884374,"version":"4.4.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1,27]]},"DOI":"10.1097\/01.tp.0000438635.44461.2e","type":"journal-article","created":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T07:59:46Z","timestamp":1386921586000},"page":"133-137","source":"Crossref","is-referenced-by-count":33,"title":["Safety of Belatacept Bridging Immunosuppression in Hepatitis C\u2013Positive Liver Transplant Recipients With Renal Dysfunction"],"prefix":"10.1097","volume":"97","author":[{"given":"John C.","family":"LaMattina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela P.","family":"Jason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven I.","family":"Hanish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane E.","family":"Ottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Klassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryn","family":"Potosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf N.","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210129","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2215\/CJN.03820609","article-title":"Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm.","volume":"4","author":"Gaston","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R2-5-20210129","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0272-6386(00)70348-9","article-title":"Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future.","volume":"35","author":"de Mattos","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"R3-5-20210129","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.","volume":"12","author":"Pestana","year":"2012","journal-title":"Am J Transplant"},{"key":"R4-5-20210129","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1432-2277.2012.01535.x","article-title":"Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study.","volume":"25","author":"Grinyo","year":"2012","journal-title":"Transpl Int"},{"key":"R5-5-20210129","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/jhep.2002.33160","article-title":"Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation.","volume":"35","author":"Nair","year":"2002","journal-title":"Hepatology"},{"key":"R6-5-20210129","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2215\/CJN.00650111","article-title":"Chronic kidney disease stage progression in liver transplant recipients.","volume":"6","author":"Lamattina","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R7-5-20210129","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00007890-199807150-00010","article-title":"Chronic renal failure following liver transplantation: a retrospective analysis.","volume":"66","author":"Fisher","year":"1998","journal-title":"Transplantation"},{"key":"R8-5-20210129","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1097\/00007890-200112270-00012","article-title":"End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.","volume":"72","author":"Gonwa","year":"2001","journal-title":"Transplantation"},{"key":"R9-5-20210129","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/lt.21821","article-title":"Renal outcomes after liver transplantation in the model for end-stage liver disease era.","volume":"15","author":"Sharma","year":"2009","journal-title":"Liver Transpl"},{"key":"R10-5-20210129","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/lt.22417","article-title":"A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.","volume":"17","author":"Klintmalm","year":"2011","journal-title":"Liver Transpl"},{"key":"R11-5-20210129","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/lt.21629","article-title":"Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study.","volume":"14","author":"Llado","year":"2008","journal-title":"Liver Transpl"},{"key":"R12-5-20210129","first-page":"S79","article-title":"Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II study.","volume":"17","author":"Garcia-Valdecasas","year":"2011","journal-title":"Liver Transpl"},{"key":"R13-5-20210129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"R14-5-20210129","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"R15-5-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-0012.2010.01238.x","article-title":"High mortality in orthotopic liver transplant recipients who require hemodialysis.","volume":"25","author":"Zand","year":"2011","journal-title":"Clin Transplant"},{"key":"R16-5-20210129","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/jlts.2001.21304","article-title":"Posttransplantation dialysis-associated infections: morbidity and impact on outcome in liver transplant recipients.","volume":"7","author":"Singh","year":"2001","journal-title":"Liver Transpl"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.TP.0000438635.44461.2e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T20:03:22Z","timestamp":1620936202000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201401270-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,27]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/01.tp.0000438635.44461.2e","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,27]]}}}